|MDACC Study No:||2011-0336 (clinicaltrials.gov NCT No: NCT01464034)|
|Title:||A Multi-Center Phase I/II, Open-Label, Dose-Finding Pilot Study of the Combination of Carfilzomib and Pomalidomide with Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma|
|Principal Investigator:||Jatin J. Shah|
|Treatment Agent:||Carfilzomib; Dexamethasone; Pomalidomide|
|Study Description:||The goal of Part I of this clinical research study is to find the highest |
tolerable dose of the combination of the drugs carfilzomib, pomalidomide, and
dexamethasone that can be given to patients with MM. The goal of Part II is to
learn if this drug combination can help to control MM. The safety of this drug
combination will also be studied. This study includes both a Part A and Part B
Phase I and Phase II portion.
Carfilzomib is designed to keep cancer cells from repairing themselves. If the
cancer cells cannot repair themselves, this may cause them to die.
Pomalidomide is designed to change the immune system, which may interfere with
the development of blood vessels that help support tumor growth. This may
reduce or stop the growth of cancer cells.
Dexamethasone is a corticosteroid that is similar to a natural hormone made by
your body. Dexamethasone is often given to MM patients in combination with
other chemotherapy to treat cancer.